Intrathecal mafosfamide: A preclinical pharmacology and phase I trial

Journal of Clinical Oncology

Volumn 23, Issue 7, 2005, Pages 1555-1563

  Blaney, Susan M ^d   Balis, Frank M ^e   Berg, Stacey ^e   Arndt, Carola A S ^e   Heideman, Richard ^a   Geyer, J Russell ^e   Packer, Roger ^e   Adamson, Peter C ^b   Jaeckle, Kurt ^c   Klenke, Renee ^e   Aikin, Alberta ^e   Murphy, Robert ^e   McCully, Cynthia ^e   Poplack, David G ^e  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c MAYO CLINIC   (United States)

^d TEXAS CHILDREN S CANCER CENTER   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAFOSFAMIDE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE;

ADOLESCENT; ADULT; AGITATION; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID CYTOLOGY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DIZZINESS; DOSE RESPONSE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; FACE EDEMA; FACE PAIN; FEMALE; FLUSHING; HEADACHE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MENINGIOMA; NAUSEA; NECK PAIN; NEOPLASTIC MENINGITIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIDE EFFECT; SOMNOLENCE; VOMITING; ANIMAL; CEREBROSPINAL FLUID; FEASIBILITY STUDY; INTRASPINAL DRUG ADMINISTRATION; MACACA; MENINGITIS; METABOLISM; NEOPLASM; PRESCHOOL CHILD; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEASIBILITY STUDIES; HUMANS; INJECTIONS, SPINAL; MACACA MULATTA; MENINGEAL NEOPLASMS; MENINGITIS; NEOPLASMS; TREATMENT OUTCOME;

EID: 20144373178     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.053     Document Type: Article

References (24)

1. Bomgaars L, Chamberlin M, Poplack D, et al: Leptomeningeal metastases (ed 2), in Levin V (ed); Cancer in the Nervous System. New York, NY, Oxford University Press, 2002, pp 373-393
2. Patel M, Blaney S, Balis F: Pharmacokinetics of drug delivery to the central nervous system, in Grochow L, Ames M (eds): A Clinician's Guide to Chemotherapy, Pharmacokinetics and Pharmacodynamics. Philadelphia, PA, Williams & Wilkins, 1997, pp 67-90
3. Kesari S, Batchelor TT: Leptomeningeal metastases. Neurol Clin 21:25-66, 2003
4. Roy P, Yu LJ, Crespi CL, et al: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666, 1999
5. Alberts D, Einsphar J, Struck R, et al: Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Inv New Drugs 2:1411-1418, 1984
6. Atassi G, Hilgard P, Pohl J: Antineoplastic activity of ASTA Z 7557 (NSC-34582, INN mafosfamide) on transplantable murine tumors. Inv New Drugs 2:169-173, 1984
7. Bruntsch U, Groos F, Hiller T, et al: Phase I study of mafosfamide-cyclohexlyamine (ASTA-Z-7557, NSC 345842) and limited phase I data on mafosfamide-lysine. Cancer Chemother Pharm 16:182-183, 1986
8. Abele R, Aapro M, Haefliger J, et al: Phase I study of cyclohexylamine and lysine salt of mafosfamide. Cancer Chemother Pharm 16:182-183, 1986
9. McCully C, Balis F, Bacher J, et al: A Rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Animal Sci 40:520-525, 1990
10. Park C, Bergsagel D, McCullough E: Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 46:411-422, 1971
11. Guide for the Care and Use of Laboratory Animals. DHEW Publication (NIH) 85-23, Revised 1988
12. Alacron J: Fluorometric determination of acrolein and related compounds with m-aminophenol. Anal Chem 30:1704-1708, 1968
13. Knott G: MLAB: A mathematical modeling tool. Comput Programs Biomed 10:271-280, 1979
14. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
15. Gibaldi M, Perrier D: Estimation of areas in Pharmacokinetics (2nd ed). New York, NY, Marcel Dekker Inc. 1982, pp 445-449
16. Blaney S, Poplack D: New cytotoxic drugs for intrathecal administration. J Neuro-Oncol 38:219-223, 1998
17. Blaney SM, Heideman R, Berg S, et al: Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21:143-147, 2003
18. Berg S, Balis F, Zimm S, et al: Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 10:143-148, 1992
19. Adamson P, Balis F, Arndt C, et al: Intrathecal 6-mercaptopurine: Preclinical pharmacology, phase I/II trial, and pharmacokinetic study. Cancer Res 51:6079-6083, 1991
20. Blaney S, Cole D, Balis F, et al: Plasma and CSF pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53:725-727, 1992
21. Blaney SM, Cole DE, Godwin K, et al: Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 36:121-124, 1995
22. Kim S, Chatelut E, Kim J, et al: Extended CSF cytarabine exposure following intrathecal administration of DTC 10l. J Clin Oncol 11:2186-2193, 1993
23. Egorin MJ, Zuhowski EG, McCully CM, et al: Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res 8:2437-2442, 2002
24. Slave I, Schuller E, Czech T, et al: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 38:213-218, 1998